SD 727-0408-APIL

AMDIPHARM

Locacorten®-Vioform®

Cream, paste and ointment

Topical corticosteroid plus antimicrobial agent

Composition

1-g cream, paste or ointment contains:

Active ingredients:

flumetasone pivalate 0.2 mg, clioquinol 30 mg.

Excipients (cream only):

lauryl sulphate, phenoxyethanol

Properties/ Actions

Flumetasone pivalate is a moderately potent synthetic fluorinated glucocorticoid for topical use with anti-inflammatory, anti-allergic, vasoconstrictor and antiproliferative properties. It provides rapid relief to symptoms such as pruritus in a wide range of aetiologically diverse inflammatory skin disorders.

Study results show that the multiple effects of glucocorticoids are due to a complex molecular mechanism in which binding to specific cytoplasmic receptors play a prominent role.

Clioquinol, the antimicrobial constituent of Locacorten-Vioform is halogenated derivative of quinolinol with activity against a wide spectrum of pathogenic micro-organisms. Its minimum inhibitory concentration (MIC) is 10 µg/ml against both moulds such as trichophyton, candida and microsporum, and most gram-positive bacteria, notably micrococcus epidermidis and lysodeikticus, staphylococcus aureus and lactis, streptococcus haemolyticus and pneumonia, and mycobacterium smegmatis and phlei.

Clioquinol has only moderate inhibitory activity against gram-negative bacteria, particularly pseudomonas aeruginosa and serratia marcescens (MIC 100 µg/ml) and therefore there is some risk of selective proliferation of such resistant species, especially pseudomonas.

Clioquinol is bacteriostatic rather than bactericidal.

Cream

The cream is hydrophilic, non-sticky and non-greasy.

It has a cooling effect and is in the form that is most suitable for use in acute subacute conditions.

Paste

The paste is a hydrophilic emulsion containing titanium dioxide. It has a cooling, drying and detumescent effect on the skin and is most suitable for acute and especially weeping lesions. It adheres well to the skin and protects it.

Ointment

The base of the hydrophilic ointment is white soft paraffin. Its lubricating effect makes it suitable for dry and chapped skin and for long term use in chronic conditions as a follow-up to use of the paste or cream during acute phase.

Pharmacokinetics

Flumetasone pivalate

Percutaneous absorption of flumetasone pivalate is not demonstrable, even after the application of large amounts to extensive areas of diseased skin and with an occlusive dressing. The effect on variables such as plasma hydrocortisone and urinary elimination of 17-ketosteroids and 17-hydroxycorticosteroids is minimal. The percutaneous absorption of flumetasone pivalate is not altered by the presence of clioquinol in the formulation.

Clioquinol

The percutaneous absorption of clioquinol was 3-5% when Locacorten-Vioform ointment or cream was applied at doses equivalent to 0.48-0.89 g clioquinol/day to lesions covering 30-70% of total body surface area. Plasma clioquinol reaches a plateau of 0.3-1.3 µg/ml after one day's treatment and falls to a negligible level within 4 days following withdrawal.

The plasma half-life varies between 19 and 30 hours.

After an oral dose of 750 mg, a plasma peak of 10 µg/ml is attained within 4 hours and the plasma half-life is 11-14 hours.

Clioquinol is excreted principally in glucuronide form and to a lesser extent as sulphate conjugates. Only traces of unchanged clioquinol appear in urine.

Indications / Uses

Primary treatment of steroid responsive inflammatory skin disorders where secondary infection has occurred with microorganisms sensitive to clioquinol, e.g.:

- seborrhoeic dermatitis, contact dermatitis atopic dermatitis, localised neurodermatitis;
- intertrigo;
- pyoderma (e.g. impetigo) and superficial fungal infections in which acute inflammation is the dominant feature;
- secondarily infected insect stings and bites.

Dosage / Administration

A thin layer of Locacorten-Vioform should be spread on the area to be treated two or three times a day, depending on the severity of the condition. The cream and ointment may be gently rubbed in to aid penetration, while the paste should be left as a visible thin layer on the surface of the skin.

A protective dressing is not necessary and occlusive dressings should not be used because of the increase in protein-bound iodine (PBI).

Restrictions on use

Contraindications

Hypersensitivity to flumetasone pivalate or corticosteroids in general, clioquinol, hydroxyquinolines or other quinoline derivatives, iodine, or any of the other substances contained in the preparation. Not to be used in viral skin infections such as varicella, cutaneous vaccination reactions, herpes simplex and herpes zoster; syphilis; cutaneous tuberculosis; rosacea; perioral dermatitis; acne vulgaris; nappy (diaper) rash or application to the eyes. Not to be used in children under 2 years of age.

31026279

cdl PRINT SOLUTIONS

Received Date:	20/11/2012
CDL JOB No. :	57222
Required By :	22/11/2012

AMDIPHARM

PRODUCT NAME:	Locacorten-Vioform Cream 0.02/3% 15g
PIP CODE:	SD 727-0408-APIL
COMPONENT:	Leaflet
SIZE:	150x200 mm
MARKET:	Sudan
PRODUCT SITE:	TBC
SCALE:	100%
COLOURS:	Black
DATE:	20/11/2012
FONT SIZE:	8 pt
VERSION NO:	3
AMENDED BY:	VK
PROJECT:	Amdipharm

REGULATORY AUTHORITY APPROVAL CONFIRMATION

Confirmation that this artwork has been approved by the appropriate market authority (if applicable, e.g. MHRA, IMB, etc and that Amdipharm have license approval to distribute this component for sale in the relevent market.

Accept Artwork .....

Reject Artwork .....

Signature .....

Name .....

Date .....

Precautions
Locacorten-Vioform should only be applied in large amounts or over extensive areas of skin in exceptional cases and under regular medical supervision. It should never be applied over relatively extensive areas or to eroded skin for longer than one week (see **Overdosage**). Long term application to the face and particularly the eyelids should be avoided.
Locacorten-Vioform is also unsuitable for use with an occlusive dressing (see **Dosage/Administration**).
If no improvement occurs after about one week, treatment should be discontinued. The pathogenic agent(s) should then be identified and appropriate treatment instituted.
Experience to date suggests that flumetasone pivalate is not absorbed to any significant extent and undesirable systemic effects, such as suppression of adrenal function, are therefore unlikely if the preparation is used as directed. The risk should however be borne in mind on basic medical grounds, especially in paediatric use.

Locacorten-Vioform monotherapy is unsuitable for primary bacterial or superficial fungal infections.
Locacorten-Vioform must not come into contact with conjunctiva. Do not use Locacorten-Vioform in the external auditory canal if the eardrum is perforated.
Care must be taken in patients with liver and/or kidney failure.
The ointment should not be used to treat acute dermatitis (especially weeping forms) or on seborrhoeic skin or skin that is sensitive to greasy substances.
Contact with Locacorten-Vioform may change the colour of hair and stain clothes and bedding.

Pregnancy/ Lactation
Pregnancy category C. Although not carried out specifically with Locacorten-Vioform, animal experiments designed to assess the safety of corticosteroids have demonstrated either teratogenic potential or other adverse effects on the embryo and /or foetus. Animal experiments with clioquinol on the other hand have revealed no embryotoxic or teratogenic effects. To date, there have been no reports of unwanted effects in pregnant women but
Locacorten-Vioform should only be used during pregnancy if strictly indicated, and even then only if the potential benefit outweighs the risk to the foetus.
This applies in particular to its use in large amounts, over extensive areas, or on a long-term basis.
It is not known whether the active ingredients of Locacorten-Vioform and /or their metabolites pass into breast milk after topical application. In the interests of safety therefore mothers who are breast-feeding should not use this preparation.

Adverse reactions
Uncommon: local irritation such as burning, itching or skin rash.
Although the risk of slight thinning of the skin is low with flumetasone pivalate, as a moderately potent corticosteroid, it should be bourne in mind where application tot he face and longer term use are concerned.
Treatment should be discontinued if irritation or severe sensitization occurs.
Local adverse reactions described with topical glucocorticoid use include contact allergy, changes in skin pigmentation and secondary infection.
Particularly when applied for long periods, to extensive areas with an occlusive dressing, or to sites with high skin permeability (eg: the face and armpits), striae rubrae distensae, telangiectasia, purpura and steroid acne may also occur.
Locacorten-Vioform must be used in accordance with the instructions given in the sections **Dosage/Administration** and **Restrictions on use.** As far as is currently known, it is unlikely that the percutaneous absorption of Locacorten-Vioform is such as to cause undesirable systemic effects such as optic nerve atrophy or peripheral neuropathy.

Interactions
No incompatibilities with other drugs have been reported to date.

Overdosage
The application of Locacorten-Vioform to eroded or extensive areas of skin, even for one week, can lead to increased PBI levels and symptoms suggesting hyperthyroidism. PBI may also be raised if relatively small areas are treated for more than one week. If this happens, treatment with the preparation should be discontinued immediately.
To date no cases of acute intoxication have been reported, but this possibly cannot be ruled out in the event of accidental ingestion by children. This would result in minor gastrointestinal reactions, with nausea and vomiting. There are no specific antidotes.

Other information
Effect on diagnostic tests
The use of Locacorten-Vioform may increase the PBI level in patients with normal thyroid function and consequently interfere with the results of thyroid function tests such as the determination of PBI, radioactive iodine uptake and thyroid hormone level (butanol-extractable iodine).
Such tests cannot therefore be carried out less than one month after discontinuation of the treatment.
Other tests of the thyroid function such as the T_3 resin uptake test and the T_4 determination, are not affected by Locacorten-Vioform. The ferric chloride test for phenylketonuria may give a false positive result in the presence of clioquinol.

Note
Medicines should be kept out of the reach and sight of children.

Storage / Shelf Life
Store below 30°C.
The preparation should not be used after the date marked <<EXP>> on the pack.

Pack Size
Cream, paste and ointment: tubes of 15 g.

Manufacturer
See outer carton.

Date of revision of text: October 2012.

Amdipharm Limited, Ireland

31026279

cdl PRINT SOLUTIONS

Received Date:	20/11/2012
CDL JOB No. :	57222
Required By :	22/11/2012

AMDIPHARM

PRODUCT NAME:	Locacorten-Vioform Cream 0.02/3% 15g
PIP CODE:	SD 727-0408-APIL
COMPONENT:	Leaflet
SIZE:	150x200 mm
MARKET:	Sudan
PRODUCT SITE:	TBC
SCALE:	100%
COLOURS:	Black
DATE:	20/11/2012
FONT SIZE:	8 pt
VERSION NO:	3
AMENDED BY:	VK
PROJECT:	Amdipharm

REGULATORY AUTHORITY APPROVAL CONFIRMATION

Confirmation that this artwork has been approved by the appropriate market authority (if applicable, e.g. MHRA, IMB, etc and that Amdipharm have license approval to distribute this component for sale in the relevent market.

Accept Artwork .....

Reject Artwork .....

Signature .....

Name .....

Date .....